Top Medical News
3 hours ago
Intraperitoneal chemotherapy is well tolerated in women with stage IIIC or IVA epithelial ovarian cancer (EOC) treated with neoadjuvant chemotherapy and optimal debulking surgery, as well as improves progressive disease rate compared with chemotherapy administered intravenously, according to the results of a phase II study.
23 hours ago
Combination treatment with dabrafenib plus trametinib demonstrates robust clinical activity in BRAF V600E–mutated anaplastic thyroid cancer (ATC), according to a phase II study.
Robotic, as compared to open, inferior vena cava thrombectomy achieves more favourable perioperative results and similar oncologic outcomes for renal tumours with level I to II inferior vena cava tumour thrombus, suggests a recent study.
Dr. Joseph Delano Fule Robles, Yesterday

A team of experts has just launched Hong Kong’s first collaborative pharmacogenomics study using next-generation sequencing (NGS) technology to identify mutation targets in patients with treatment-resistant/relapsed ovarian cancer (OC) towards a more personalized approach in management. 

4 days ago
It is recommended that the duodenum be examined when performing oesophagogastroduodenoscopy (EGD), regardless of the indication, as the procedure can detect duodenal carcinoma in its early stage in asymptomatic patients, according to a study.
4 days ago
Hydrochlorothiazide (HCTZ) appears to significantly increase the risks of nonmelanoma skin cancer (NMSC), particularly squamous cell carcinoma (SCC), a recent study has shown.
Jairia Dela Cruz, 4 days ago
The presence of large tumours harbouring malignant heterologous elements may predict the development of metastasis in women with malignant phyllodes tumours of the breast, according to a Singapore study.
Special Reports
04 Dec 2017
Management of locally advanced hepatocellular carcinoma aims to improve survival and to maintain the quality of life of patients, with less likelihood of cure due to the advanced nature of disease. Upon diagnosis of the severity of liver cancer, offering appropriate and proven treatment options is important to extend the survival of these patients.
Dr Joslyn Ngu, 04 Dec 2017

Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.

Dr Joslyn Ngu, 04 Dec 2017

Incorporating polygenic risk scores based on 18 SNPs (single nucleotide polymorphisms) into risk stratification for breast cancer will improve screening results, says an expert.

Dr Joslyn Ngu, 04 Dec 2017

Making genetic testing mainstream, allows more patients to be tested, identifies more carriers and enables appropriate stratification of treatment and outcomes, says an expert.

Dr Joslyn Ngu, 04 Dec 2017

Hereditary breast and ovarian cancer (HBOC) syndrome, which is primarily caused by BRCA1 and BRCA2 mutations, make up 8 to 10 percent of all breast cancers, says a senior consultant.

Dr Joslyn Ngu, 04 Dec 2017

Genetic testing has changed the landscape of lung cancer and every patient needs to undergo testing, says a specialist.

Dr Joslyn Ngu, 04 Dec 2017

Identification of BRCA mutation in ovarian cancer is vital because it allows better risk management and there is evidence that carriers may benefit from new treatment modalities, said Professor Woo Yin Ling, consultant gynaecological oncologist at the University of Malaya. 

Conference Reports
Dr Joslyn Ngu, 04 Dec 2017

MIMS Doctor spoke to Dr Kho Sze Shyang, of Sarawak General Hospital, who won not one, but two awards at the recent International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC), held in Yokohama, Japan. The two papers that Kho submitted won him the IASLC International Mentorship Program and the WCLC 2017 Developing Nation Travel Awards.

Roshini Claire Anthony, 28 Nov 2017

Survival outcomes of women diagnosed with breast cancer during pregnancy are similar to that of non-pregnant women, according to a presentation at ESMO Asia 2017. However, it is important to identify the dos and don’ts when diagnosing and treating breast cancer in this population.

Pearl Toh, 27 Nov 2017
Treatment with the PD-L1* inhibitor durvalumab after chemoradiotherapy significantly prolongs progression-free survival (PFS) by 11 months in patients with locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC), with similar benefits in an Asian subset, according to the PACIFIC** study presented at ESMO Asia 2017 in Singapore.
27 Nov 2017
Slideshow: Highlights from ESMO Asia 2017 Congress
Stephen Padilla, 27 Nov 2017
A week-on week-off (WOWO) gemcitabine/nab-paclitaxel (gem/nab-P) regimen appears to be as effective but potentially less toxic than standard gem/nab-P for advanced pancreatic cancer, according to a study presented at the European Society for Medical Oncology (ESMO) Asia 2017 Congress.
Tristan Manalac, 26 Nov 2017
Consistent with literature findings, palbociclib is generally well-tolerated and effective in controlling the disease of Asian patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC), reports a new study from Hong Kong presented at the recently concluded European Society for Medical Oncology (ESMO) Asia 2017 Congress.
Tristan Manalac, 26 Nov 2017
Regorafenib appears to have promising efficacy as a third- or fourth-line treatment for patients with metastatic colorectal cancer (mCRC), according to a new study from Macau presented at the recently concluded European Society for Medical Oncology Asia 2017 Congress (ESMO Asia 2017).
Product Highlights
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!